.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Moodys
Deloitte
Covington
US Department of Justice
Cipla
Johnson and Johnson
QuintilesIMS
Queensland Health
Boehringer Ingelheim

Generated: September 25, 2017

DrugPatentWatch Database Preview

Dr Reddys Labs Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DR REDDYS LABS INC, and when can generic versions of DR REDDYS LABS INC drugs launch?

DR REDDYS LABS INC has forty-one approved drugs.

There are five US patents protecting DR REDDYS LABS INC drugs. There are two tentative approvals on DR REDDYS LABS INC drugs.

There are ninety-four patent family members on DR REDDYS LABS INC drugs in forty-eight countries.

Summary for Applicant: Dr Reddys Labs Inc

Patents:5
Tradenames:34
Ingredients:26
NDAs:41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Inc
FLUCONAZOLE
fluconazole
TABLET;ORAL076658-002Jul 29, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
AUGMENTIN '250'
amoxicillin; clavulanate potassium
FOR SUSPENSION;ORAL050575-002Aug 6, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
ZIPRASIDONE HYDROCHLORIDE
ziprasidone hydrochloride
CAPSULE;ORAL077565-002Mar 2, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
AMOXIL
amoxicillin
CAPSULE;ORAL062216-004Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
IBUPROFEN
ibuprofen
TABLET;ORAL076117-001Nov 20, 2001OTCNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
SIMVASTATIN
simvastatin
TABLET;ORAL077752-004Dec 20, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
AUGMENTIN '125'
amoxicillin; clavulanate potassium
TABLET, CHEWABLE;ORAL050597-001Jul 22, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
SIMVASTATIN
simvastatin
TABLET;ORAL077752-002Dec 20, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
naproxen sodium; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL077381-001Sep 27, 2006OTCNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
NEFAZODONE HYDROCHLORIDE
nefazodone hydrochloride
TABLET;ORAL076309-002Sep 16, 2003BXRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DR REDDYS LABS INC drugs

Drugname Dosage Strength Tradename Submissiondate
amoxicillin and clavulanate potassium
Extended-release Tablets1000 mg/62.5 mg
AUGMENTIN XR
1/21/2009

Non-Orange Book Patents for Dr Reddys Labs Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin► Subscribe
6,660,299 Modified release pharmaceutical formulation comprising amoxycillin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Dr Reddys Labs Inc Drugs

Country Document Number Estimated Expiration
Hungary0200831► Subscribe
MexicoPA01010377► Subscribe
Slovakia285140► Subscribe
Japan2002541187► Subscribe
Colombia5170471► Subscribe
Czech Republic20001311► Subscribe
Greece1003560► Subscribe
Romania120817► Subscribe
Malaysia119953► Subscribe
Australia771639► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Dr Reddys Labs Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00524Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2014 00037Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2008013Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
2008013,C1412357Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
12/018Ireland► SubscribePRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
00499Netherlands► SubscribePRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
2012000051Germany► SubscribePRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
/1998Austria► SubscribePRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
2014 00037Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
McKesson
Accenture
Citi
Chubb
Boehringer Ingelheim
US Army
Johnson and Johnson
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot